Donald Trump has indicated a potential delay on tariffs for pharmaceutical companies set to be imposed due to sector-specific import taxes. During a meeting with industry leaders at the White House, he suggested that drugmakers could avoid these taxes by moving operations back to the US and will be given time to make this transition. His recent remarks imply a willingness to reconsider aggressive tariff policies amid backlash against their economic repercussions, as companies have expressed significant investment intent in the US to avoid these tariffs.
Trump suggested that if pharmaceutical companies move operations to the US, they will not face tariffs, giving them time to make the transition.
The president's hints at delaying tariffs reflect the growing opposition to these measures and their impact on the business environment.
At the White House meeting, it was reported that businesses pledged up to $8 trillion in investment, hoping to dodge tariffs by expanding in the US.
Trump emphasized that the pharmaceutical sector could be the latest industry to benefit from a pause or dilution of tariffs due to mounting pushback.
Collection
[
|
...
]